Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

NCT06451198 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT06451198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06451198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
May 19, 2025
Completion date
December 31, 2028
Enrollment
2,846 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiplatelet drugs, coronary artery disease